Navigation Links
NewCardio Announces Positive Results From Third Clinical Validation Study
Date:8/13/2008

Test validates QTinno(TM) - proves the ability to automatically measure QT

intervals in even challenging samples

SANTA CLARA, Calif., Aug. 13 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today revealed the results of its third external validation study of QTinno(TM) (the "NCE3 Study"). The study was led by an independent industry leading cardiac safety expert with extensive experience in pharmaceutical clinical trials. The study evaluated the accuracy, precision and speed of NewCardio's lead product, QTinno(TM), in producing fully automated measurements of drug-induced QT prolongation, a key cardiac safety indicator. Such data is now required by drug regulatory bodies worldwide for all new drugs in development, and at present must be obtained by expensive and time-consuming manual or semi-automated methods.

The NCE3 study was a randomized, blinded study of more than 2,500 digital ECGs acquired from healthy research subjects treated with either placebo or a cardiac drug with significant QT-prolonging properties and a known propensity to cause serious cardiac arrhythmias. QT intervals were determined on all study ECGs by QTinno(TM) and by the current "gold standard" approach: careful manual reading by a single cardiologist with extensive expertise and experience in ECG evaluation. The primary endpoint, time-matched, placebo-controlled QT prolongation induced by drug, was chosen because drug-induced QT prolongation is the primary parameter that regulatory bodies evaluate to assess the cardiac arrhythmia risk of a new drug candidate.

Results from the NCE3 study showed that QTinno(TM) was accurate in measuring drug-induced QT prolongation. The automated determination derived at by QTinno(TM) and the "gold standard" manual measurement were virtually identical (well under 1 millisecond difference), and individual measurements showed a high degree of precision (
'/>"/>

SOURCE NewCardio, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
2. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
3. Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
4. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
5. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
6. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
7. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
8. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
9. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
10. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
11. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- Research and Markets  has announced the addition of ... report to their offering. The Central Nervous ... largest segments of pharmaceuticals industry. The numbers of CNS disorders ... were unable to meet the market requirements. There has been ... especially over the past two decades. The market for CNS ...
(Date:8/29/2014)... Vittamed Corporation , a neurodiagnostics medical device company based in ... (Teo) Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, FRCSEd ... " Teo Forcht Dagi is an experienced leader ... capital," said Remis Bistras , President and CEO of ... and entrepreneurial expertise to our Board." Dr. Dagi ...
(Date:8/29/2014)... -- Research and Markets has announced the ... 2014-2018" report to their offering. ... results in demyelination, axonal transection, and neurodegeneration. The myelin ... the immune system, which targets neurons within the central ... in which the damage of the myelin sheath causes ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... June 29 Noting that only about 200 of the nearly 7,000 ... today called for a Food and Drug Administration (FDA) statement of policy on regulation ... , NORD also urged ... of medicines for rare disorders. , , ...
... , DAYTON and CINCINNATI, Ohio , June 29 ... with Stipkala LLC, was an invited speaker and panel discussion participant at ... in Dayton, Ohio June 16-19, 2010 .  The 2010 ... new technologies in addition to traditional chemical disciplines.   , ...
Cached Medicine Technology:NORD Calls for Statement of Policy on Orphan Drug Development 2Dr. Harry J. Guttman, Esq. Invited Speaker at 2010 Central Regional Meeting of the American Chemical Society 2
(Date:9/1/2014)... (PRWEB) September 02, 2014 Top10BestSEOHosting.com is ... recently compared many top web hosting companies and announced ... hosting suppliers in August. , GreenGeeks ( http://www.greengeeks.com/cgi-bin/affiliates/clickthru.cgi?id=seohosts ... from the USA. The company has a lot of ... always get great products at low rates. , ...
(Date:9/1/2014)... was associated with mental health and substance use ... protect teens from the consequences of cyberbullying and ... Author: Frank J. Elgar, Ph.D., of McGill University, ... in 5 adolescents has experienced recent online bullying ... risk of mental health problems in teens as ...
(Date:9/1/2014)... 01, 2014 Liver is the largest organ ... that helps the body in barring itself from poisons, helps ... energy. Liver also plays many important functions such as protein ... , Many illnesses can affect the liver, an organ ... cage on the right side of the abdomen, reducing its ...
(Date:9/1/2014)... The B-cell non-Hodgkin’s Lymphoma (NHL) treatment ... markets (the US, France, Italy, Germany, Spain and the ... by 2018. , The competitive landscape in the B-cell ... and the UK is poised to undergo a dramatic ... four largest B-cell NHL indications, which includes Diffuse Large ...
(Date:9/1/2014)... D.C. (PRWEB) September 01, 2014 The ... pleased to announce that Dawn Bazarko, DNP, MPH, RN, ... Fellows of the American Academy of Nursing. They will ... MBA, RN-BC, CCM, FACHE, whose induction we reported last ... October 18, 2014, during the 2014 American Academy of ...
Breaking Medicine News(10 mins):Health News:The Best Reseller Hosting Suppliers in August Released by Leading Review SiteTop10BestSEOHosting.com 2Health News:Family dinners good for teens' mental health, could protect from cyberbullying 2Health News:Family dinners good for teens' mental health, could protect from cyberbullying 3Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 2Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4
... in the early detection of coronary heart disease (CHD) between ... 45-64 have undetected or silent myocardial infarctions, suggesting a general ... a doctors gender may hinder early hinder early diagnosis of ... by Dr Ann Adams of Warwick Medical School at the ...
... indoor mould improves the symptoms of people with asthma. , ... is among the highest in the world, with 260,000 people ... admissions for adults 12 per cent more than anywhere else ... asked patients with asthma living in two areas of South ...
... Memry Corporation,(Amex: MRY ), a leading provider ... announced today that it will release its fiscal,fourth quarter ... 17,after the market closes. The company will host ... of the management team on Tuesday, September 18 at ...
... ... Refined Cats, Palates, CHELMSFORD, Mass., Sept. 5 ... natural food and treats for pets,is launching a NEW offering for ... real,seafood and poultry morsels and an array of fresh fruits and ...
... choices for older Americans, researchers find , WEDNESDAY, Sept. ... that charge higher co-pays for brand name or non-preferred ... peers who have a flat co-pay for all prescription ... a tough decision for older Americans: Spend more or ...
... Medical,Organizations Growing Rapidly with Thousands of Community Members ... introduced Lance Hill,as the new CEO of the ... physicians, researchers, and medical organizations worldwide. Members,use Within3,s ... as a,professional tool, where they can develop their ...
Cached Medicine News:Health News:Research says doctor's gender may hinder early diagnosis of heart disease in women 2Health News:Research says doctor's gender may hinder early diagnosis of heart disease in women 3Health News:Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call 2Health News:Finicky Felines Award Four Stars to New Wellness(R) Healthy Indulgence Everyday Entrees 2Health News:Finicky Felines Award Four Stars to New Wellness(R) Healthy Indulgence Everyday Entrees 3Health News:High Co-Pays Cause Seniors to Go Without Meds 2Health News:Cleveland-based Health Care Tech Company Within3 Names New CEO 2
... Mini low cost Incubators. Bench top ... excellent incubation results. Aluminum lined chamber ... and I104025 incubators contain removable perforated ... easy decontamination. Thermometer port on top ...
Binocular indirect ophthalmic lenses. Pediatric ophthalmoscopy / vetinary applications....
Binocular indirect ophthalmic lenses. Small pupil diagnosis & treatment....
Binocular indirect ophthalmic lenses. General diagnosis & treatment....
Medicine Products: